Posts

Showing posts with the label pre-exposure prophylaxis

COVID: hydroxychloroquine post-exposure prophylaxis

A randomized trial did not find benefit of hydroxychloroquine used as postexposure prophylaxis for Covid-19 ( see  covid hydroxychloroquine PEP nejm2020  in dropbox or DOI: 10.1056/NEJMoa2016638 )   Details: -- 821 asymptomatic people from the United States and Canada exposed to someone with confirmed Covid-19 were randomized to hydroxychloroquine (800 mg x1, 600 mg 6 to 8 hours later, then 600 mg daily for 4 more days, for a total course of 5 days) vs placebo -- exposure: household or occupational exposure to someone with known Covid-19, at a distance of less than 6 feet   for more than 10 minutes while wearing neither a facemask nor an eye shield (high risk exposure) or whiole wearing a facemask but no eye shield (moderate risk exposure) -- median age 40, 52% women, 27% with chronic health conditions (hypertension 12%, asthma 8%) -- 66% of the participants were healthcare workers, majority being physicians or physicians assistants (63%) and nurses are nursing ...

PrEP, another blog

Image
PrEP, another blog here is another blog on the FDA approval of tenofovir alafenamide (TAF) combined with emtricitabine (FTC) for preexposure prophylaxis to prevent HIV transmission, written by Jon Pincus and sent with his permission. the advantage of TAF over  tenofovir disoproxil (TDF) is its decreased renal/bone toxicities. Jon  goes into more depth than i did and has a somewhat different angle, so i thought it might be useful to pass around. his email/blog is in response to questions circulating around about the benefit of this new FDA recommendation. ------------------------------------------------------------------------------------------------------ In summary - I would not use TAF yet for PrEP though in theory it might be better for PWID (people who inject drugs), I think we need to focus on getting and keeping folks on PrEP and not on which drug to use and that the push towards TAF is also problematic given the huge cost differentia...

2016 HIV treatment guidelines

The International Antiviral Society--USA panel just released their 2016 recommendations for antiretroviral drugs for treatment and prevention of HIV infection in adults (see  hiv guidelines adult rx jama2016 ​ in dropbox, or Gunthard HF. JAMA 2016; 316(2): 191; and this group did include several HIV luminaries, such as Paul Sax from Brigham & Women's and Paul Volberding from UCSF). summary: --when to initiate therapy:     --everyone who has detectable virus, independent of CD4 count; and as soon as possible after acute HIV infection (to reduce the latent HIV reservoir, immune activation and perhaps protection against infection of central memory T cells)     --also in those with persistent undetectable virus without ART (antiretroviral therapy) if declining CD4 counts, which can occur in these "elite controllers", since they have higher levels of immune activation and increased cardiovascula...